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Objectives: Extensively drug-resistant tuberculosis (XDR-TB) is more expensive
and difficult to treat than multidrug-resistant TB (MDR-TB) and outcomes for
patients are much worse, therefore understanding the magnitude and distribu-
tion of XDR-TB is important. A retrospective study was conducted to estimate the
incidence of and risk factors for, multidrug XDR-TB (M/XDR-TB) as compared to
susceptible controls.
Methods: Sputum culture and drug susceptibility testing (DST) were done for
patients with known or suspected TB. The strains that were identified as MDR
were subjected to DST for second line drugs (SLD) by using the proportion method.
Results: Among 1,442 TB patient cases (mean age, 46.48  21.24 years) culture-
positive for Mycobacterium tuberculosis, 1,126 (78.1%) isolates were resistant to
at least one first line drug; 33 cases (2.3%) were MDR-TB, of which, three isolates
(0.2%) were classified as having XDR-TB. Ofloxacin resistance was found in 10
(0.7%) isolates. The odds of having M/XDR-TB were found to be 15% higher among
females than males, but the difference was not significant. In the multivariate
analysis, only one variable, number of previous treatment regimens, was associ-
ated with MDR as compared to susceptible TB [odds ratio (OR) 1.06, 95% confi-
dence intervals (CI) 1.14e21.2].
Conclusion: The burden of M/XDR-TB cases is not sizeable in Iran. However, we
must implement strategies to identify and cure patients with pre-XDR-TB before
they develop XDR-TB. Our results help provide an understanding of the evolution
and spread of M/XDR-TB in a low-incidence setting of drug-resistant TB and its
relationship with risk factors for the assessment of future treatment changes and
interventions.mand).
ase Control and Prevention. Published by Elsevier Korea LLC. This is an open access article
reativecommons.org/licenses/by-nc-nd/4.0/).
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2 A. Hadizadeh Tasbiti, et al1. Introduction
Tuberculosis (TB) remains a major global health
problem. In 2012, an estimated 8.6 million people
developed TB and 1.3 million died from the disease [1].
The increasing incidence of multidrug and extensively
drug-resistant TB (M/XDR-TB) is a major concern for
TB control programs worldwide [2]. Moreover, the
estimated global incidence of TB is declining slowly, by
< 2% per year. To reach the TB elimination target of
< 1/1,000,000 population in 2050, the incidence needs
to decline by 20% per year [3]. At least one case of
XDR-TB had been reported by 92 countries by the end
of 2012. On average, an estimated 9.6% of multidrug-
resistant TB (MDR-TB) cases have XDR-TB [4]. The
treatment of patients with XDR-TB is usually more
complex, toxic, and costly and less effective than
treatment of other forms of TB [2]. A better under-
standing of epidemiological trends in drug resistance at
the global and national levels can be achieved only
through repeated surveys and, ultimately, by establish-
ing continuous surveillance based on routine drug sus-
ceptibility testing (DST) of all confirmed TB cases [5].
Countries with a low burden of TB that experience an
epidemic that is concentrated among specific risk groups
(factors) focus their care and prevention efforts partic-
ularly on such groups. Especially when a country is
striving to eliminate TB, and needs to invest additional
resources to effectively reach those who are hardest to
reach, screening selected high-risk groups may be a key
part of the response to TB. In addition, the primary
objective of screening is to ensure that active TB is
detected early to reduce the risk of poor disease out-
comes and the adverse social and economic conse-
quences of the disease, as well as help reduce TB
transmission [4]. By contrast, TB incidence is one of the
most important surveillance indicators reflecting the
impact of TB on public health [6]. For these reasons risk
factors relative to TB occurrence are unclear in Iran, and
there are little reported data for its effect on the overall
outcome of treatment, we conducted a population-based
retrospective study to get M/XDR-TB incidence rates
among all patients who have clinically confirmed or
suspected TB, and who are referred to the Pasteur
Institute-Tehran, Iran, to analyze the association be-
tween risk factors and resistant TB.2. Materials and methods
2.1. Setting
We performed this study in the TB department of the
Pasteur Institute, Tehran. The TB department is a gov-
ernment TB laboratory in Iran. A retrospective study was
carried out from January 2006 to October 2013 among all
patients who had clinically confirmed or suspected TB,
and were referred to the TB laboratory for culture andPlease cite this article in press as: Hadizadeh Tasbiti A, et al., Low Level
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10.1016/j.phrp.2016.06.003susceptibility testing. Patients were classified as new if
they had never been treated for TB > 4 weeks and as
previously treated if they had ever been treated for TB
for  4 weeks [7]. In Iran, Bacillus Calmette-Guerin
vaccination is given within 1 week of the birth of a
child. We conducted a TB follow-up chart review to
determine TB-related symptoms and employment status
of persons recorded at baseline by the intake physician
before they received MDR-TB therapy. In addition to
data obtained through routine patient follow-up, health
workers were interviewed to obtain additional follow-up
information about the patients.
A summary of recruitment is displayed in Figure 1.
Sputum samples (3 samples per patient) were obtained
from all patients for Mycobacterial culture and DST
before the initiation of treatment. The MDR-TB work-
ing group recommends follow-up for 12 months from
the time of treatment initiation when reporting positive
culture results. All MDR patients were tested for human
immunodeficiency virus (HIV) at the AIDS Department
of the Pasteur Institute.
2.2. Decontamination procedures
Decontamination was done with the N-acetyl-L-
cysteine-sodium hydroxide method. Cultures were done
on Lowenstein-Jensen slopes by the CDC (Centers for
Disease Control and prevention, Atlanta, GA, USA)
manual. Acid fast microscopy, to confirm the presence
of bacilli, was done on each sputum sample. All positive
cultures were identified as Mycobacterium tuberculosis
by means of a niacin test, catalase activity, nitrate
reduction, and pigment production and growth rate [8].
2.3. DST
DST for first and second line drugs (SLD) was per-
formed by absolute concentration method (MIC) for all
drugs. DST against isoniazid, rifampicin, ethambutol,
and streptomycin was performed by the proportional
method at a concentration of 0.2 mg/mL, 40 mg/mL,
2.0 mg/mL, and 4.0 mg/mL, respectively. DST against
SLD (kanamycin, capreomycin, amikacin, ofloxacin,
para-aminosalicylic acid, ethionamide, and cycloserin)
was performed using two critical proportions of 1% and
10% [9]. Drugs were procured from Sigma-Aldrich (St.
Louis, USA) and for each batch of DST, a sensitive
strain of H37Rv was used as a control.
2.4. Definition of XDR-TB
XDR-TB is defined as TB that has developed resis-
tance to at least rifampicin and isoniazid as well as to
any member of the quinolone family and at least one of
the following second line anti-TB injectable drugs:
kanamycin, capreomycin, or amikacin [10].
2.5. Statistical analysis
Risk factors were defined according to the World
Health Organization of definition of risk groups. A riskof Extensively Drug-resistant Tuberculosis Among MDR-TB Isolates
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Positive culture cases recruited in the survey 
2006–2014 
N=1442 
MDR-TB cases      n = 33 
XDR –TB cases     n = 3 
Mixed resistance*  n = 1    090
Susceptible cases 
n =  316
Admitted to study 
MDR TB cases  n = 33 
XDR-TB cases   n = 3 
Admitted to study 
Susceptible controls 
n = 121
Eligible survey population
with DST  data and complete 
records available 
n = 157 
Not admitted cases 
n = 195 
Reasons: 
- Unknown previous history 
- Incomplete DST results  
- Ambiguous records or resistance pattern 
Fig. 1. Case population. * Mixed resistance: any resistance (resistance to any of the anti-TB drugs) þ mono-resistance (resistance
to only 1 drug) þ poly-resistance (resistance to at least 2 or more drugs, but excluding the isoniazid and rifampicin combination).
CXR Z chest X-ray; DST Z drug susceptibility test; HIV Z human immunodeficiency virus; MDR Z multidrug-resistant;
SD Z standard deviation; XDR Z Extensively drug-resistant.
M/XDR-TB in Tehran-Iran: 2006e2014 3group for TB is any group of people within which the
prevalence or incidence of TB is significantly higher
than in the general population. The following risk fac-
tors were examined: age, gender, HIV, diabetes, smok-
ing, high risk job (e.g., healthcare workers), cavitations
on chest X-ray, extrapulmonary TB and people previ-
ously treated for TB. The last variable (people previ-
ously treated) was handled as a binary (Yes or No) and
labeled as “Received prior treatment” [4]. Data analysis
was conducted using SPSS version 19.0 (SPSS Inc.,
Armonk, New York, USA). Descriptors and risk factors
were compared using independent samples t test. Lo-
gistic regression was performed to compare M/XDR-TB
cases to susceptible cases and categorical variables were
compared using the c2 test and odds ratio (OR) with
95% confidence intervals (95% CI). A p value < 0.05
was considered significant.3. Results
Between January 2006 and January 2014, 1,442 pa-
tients had culture proven M. tuberculosis infections,
Figure 1. The results of susceptibility testing showed
that 1,090 isolates were mixed resistance (any resis-
tance, mono-resistance, and poly-resistance), 33 MDR-
TB, three XDR-TB, and 316 of which were suscepti-
ble to all drugs. Of 1,126 drug-resistant specimens
(mixed resistance, MDR, and XDR-TB), 33 MDR-TB,
and three XDR-TB isolates, were submitted for anal-
ysis and the remaining specimens were excluded. Of 316
cases with susceptible TB, 195 had indefinable or
incomplete clinical records available, or did not have the
entire SLD susceptibility test, so that they could not be
registered to one category, leaving 121 susceptible casesPlease cite this article in press as: Hadizadeh Tasbiti A, et al., Low Level
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10.1016/j.phrp.2016.06.003available for further analysis. Thus, of 1,442 positive
culture cases, a total of 157 isolates (121
susceptible þ 33 MDR þ 3 XDR) were admitted for
analysis. The demographic characteristics are shown in
Table 1. The patients had a mean age
46.48  21.24 years and 91 (58.0%) were females.
Forty-one patients were only extrapulmonary cases
(42.2%). Seventy-one patients were tested for HIV,
among which 12 were HIV positive (17%) and 25 had
cavitations on chest X-ray (34.2%). Among 157 pa-
tients, 129 (82.1%) were newly diagnosed patients and
28 (17.9%) were previously treated cases. There were 33
cases (21.1%) with MDR-TB, of which 16.6% were
newly treated cases, 1.3% relapse cases, and 3.2% fail-
ure cases. The XDR-TB rate was 0.6% among new cases
and 1.3% in treated cases. Table 2 shows the distribution
of these patients and classification of resistance rates
among positive culture isolates and MDR-TB cases. Of
the all culture positive patients, 58.4% had resistance
to at least one of the tested anti-TB drugs. Ofloxacin
resistance was found in 10 (0.7%, vs. positive cultures)
of the isolates. Three cases (9.0% vs. MDRs) of XDR-
TB were detected, Table 2. Thus the frequency of
XDR-TB among MTB patients was 0.2%. Three XDR-
TB patients had pulmonary diseases and these patients
were to have positive sputum smear test results.
One of the XDR-TB patients (male, 45 years) with
positive HIV infection had a definite history of previous
treatment for TB, and died. We found no significant
differences between patients with XDR-TB and patients
with MDR. Risk factors for M/XDR-TB cases are
summarized in Table 3. The odds of having M/XDR-TB
patients among HIV positive cases were found to be
25% higher than that among HIV negative cases, but the
differences was not statistically significant (data notof Extensively Drug-resistant Tuberculosis Among MDR-TB Isolates
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Table 1. Demographic data and description of patients studied.
Characteristic
Age (y) Total n Z 157
Mean  SD Susceptible MDR XDR Age (y) Frequency
n (%)
Range
<20 19 (12.1) 88.00
46.48  21.24 (46.6  21.96) (46.6  18.83) (54.00  13.07) 20e40 47 (29.9)
40e60 44 (28.1)
>60 47 (29.9)
Gender, n (%) Male Female Total
66 (42.0) 91 (58.0) 157 (100.0)
Drug resistance patterns
New cases Previously treated cases n (%) Total number of isolates (%)
n (%) Relapse Failure
Susceptible 102 (64.9) 8 (5.1) 11 (7.0) 121 (77.0)
MDR 26 (16.6) 2 (1.3) 5 (3.2) 33 (21.1)
XDR 1 (0.6) 0 (0.0) 2 (1.3) 3 (1.9)
Total 129 (82.1) 10 (6.4) 18 (11.5) 157 (100.0)
Description of cases* n (%)
HIV infection 12/71 (17.0)
Cigarette use 30/79 (38.0)
Extra pulmonary involvement 41/97 (42.2)
Cavity (CXR) 25/73 (34.2)
Received prior treatment 28/81 (34.5)
Treatment with fluo
roquinolone/injectable
4.0/47 (8.50)
High risk jobs 15/57 (26.3)
Diabetes 34/87 (39.0)
*More than 25% data unavailable. CXRZ chest X-ray; HIVZ human immunodeficiency virus; MDRZmultidrug-resistant; SDZ standard deviation;
XDRZExtensively drug-resistant.
4 A. Hadizadeh Tasbiti, et alshown). In bivariate analysis, three variables were
associated with MDR as compared to sensitive TB,
Table 3. Diabetes was associated with MDR (OR 1.01,
95% CI 1.09e30.7). Age (20e40) was negatively
associated with MDR (OR 0.17, 95% CI 0.07e0.60) as
was gender (male) (OR 0.27, 95% CI 0.18e0.78). In the
multivariate analysis, only one variable, number of
previous treatment regimens, was associated with MDR
as compared to susceptible TB (OR 1.06, 95% CI
1.14e21.2; multivariate regression data not shown).
None of 10 variables were significantly associated with
XDR-TB.4. Discussion
The present study represents a comprehensive
description on second line drug resistance among MDR-
TB isolates in a low burden country. There have been
only a few reports of M/XDR-TB published from Iran.
In a study that describes the transmission of XDR-TB
among patients with secondary cases of TB, Masjedi
et al [11] showed that 12 (10.9%) of 113 Iranian MDR-
TB strains were resistant to all eight SLD tested.Please cite this article in press as: Hadizadeh Tasbiti A, et al., Low Level
and its Relationship to Risk Factors: Surveillance in Tehran-Iran, 2006e
10.1016/j.phrp.2016.06.003Metanat et al [12] recently reported the prevalence of M/
XDR-TB in Zahedan, Southeastern Iran. In a total of 88
patients, 12.2% had MDR-TB and one with pre XDR-
TB was identified. No case had XDR-TB. Another
study diagnosed only seven XDR-TB patients treated
with the standardized regimen. This report shows a poor
prognosis in patients with XDR-TB [13]. The differ-
ences in resistance rates between the present and an
earlier study [11,13] can be explained by the difference
in the numbers of MDR-TB cases. Our study has a small
underlying population of MDR-TB cases.
A cohort study in eight countries indicated 43.7% and
12.9% resistance to at least one SLD and fluo-
roquinolone, respectively. This study showed previous
treatment with SLD was consistently the strongest risk
factor for resistance to these drugs, which increased
the risk of XDR-TB by more than four times [14]. Re-
sults of a hospital based study determined the occur-
rences of MDR and XDR-TB as 1.2% and 0.38%,
respectively, in Thailand [15] and 8.6% ofloxacin
resistance in China [16]. Ershova et al [17] recently
reported risk factors for acquired resistance to injectable
SLD and fluoroquinolones in the United States National
TB surveillance system. The baseline prevalence ofof Extensively Drug-resistant Tuberculosis Among MDR-TB Isolates
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Table 2. Frequency of first-line and second-line anti-TB drug resistance profiles among positive culture isolates and MDR-TB
cases respectively in Tehran-Iran 2006e2013.
First line rates Second line rates
Resistance profile n (%) Resistance profile n (%)
All cases n Z 1442
(MTB)
Any drug resistance Any drug resistance
EMB 169 (11.7) OFX 10 (30.3 vs MDR)
SM 330 (22.9) PAS 16 (48.5)
RIF 176 (12.2) CPM 13 (39.4)
INH 168 (11.6) KM 12 (36.3)
AMK 15 (45.4)
MDR-TB* 33 (2.3 vs MTB) CYC 15 (45.4)
INH þ RIF 2 (0.1) ETH 13 (39.4)
INH þ RIF þ EMB 7 (0.5)
INH þ RIF þ SM 9 (0.6) XDR-TB 3 (9.0 vs MDR)
INH þ RIF þ SM þ
EMB
15 (1.1) OFX þ PAS þ CPM þ KM þ AMK þ ETH 1 (3.0)
XDR-TBy 3 (0.2 vs MTB) OFX þ CPM þ AMK þ ETH 1 (3.0)
Susceptible 316 (21.9) OFX þ AMK 1 (3.0)
Mixed resistancez 1090 (75.6)
*MDR-TB; resistance to isoniazid and rifampicin; yXDR-TB; defined as MDR-TB that is also resistance to any fluoroquinolones and at least one injectable
second line drug; zMixed resistance; any resistance (resistance to any of the anti-TB drugs) þ mono-resistance (resistance to only 1 drug) þ poly-resistance
(resistance to at least 2 or more drugs, but excluding the isoniazid and rifampicin combination). AMKZ amikacin; CPMZ capreomycin; CYCZ cy-
closerine; EMBZ ethambutol; ETHZ ethionamide; INHZ isoniazid; KMZKanamaycin; OFXZ ofloxacin; PASZ Para-aminosalicylic acid;
RIFZ rifampicin.
M/XDR-TB in Tehran-Iran: 2006e2014 5MDR and XDR-TB was 12.6% and 0.38%, respectively.
These rates are not similar to our findings. The dis-
crepancies in findings are subject to at least three limi-
tations. First, the number of XDR-TB cases is a
minimum estimate because of incomplete DST data.
Initial TB isolates with any resistance to rifampin orTable 3. Risk factors of patients with MDR and XDR-TB in th
Factors* Odds ratios fo
TB, bivariate
(95% C
Age (y)
<20 0.28 (0.27e
20e40 0.17 (0.07e
40e60 0.84 (0.19e
>60 d
Gender (male) 0.27 (0.18e
HIV infection 0.09 (0.66e
Cigarette use 0.62 (0.10e
Extra pulmonary
involvement
0.30 (0.47e
Cavity (CXR) 0.56 (0.004
Received prior treatment 0.87 (0.17e
Treatment with
fluoroquinolone/
injectable
0.74 (0.15e
High risk jobs 0.13 (0.66e
Diabetes 1.01 (1.09e
*More than 25% data unavailable. CIZ confidence interval; CXRZ chest X-
drug-resistant.
Please cite this article in press as: Hadizadeh Tasbiti A, et al., Low Level
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10.1016/j.phrp.2016.06.003resistance to any two first-line drugs should be tested for
susceptibility to a full panel of anti-TB drugs, and the
results should be reported accordingly [18]. Second,
aggregate reporting of drug resistance traditionally has
been based only on initial DST results, not on drug
resistance that develops during treatment. Third, ae population (bivariate analysis).
r MDR-
analysis
I)
Odds ratios for XDR-
TB, bivariate analysis
(95% CI)
2.88) 0.97 (0.35e1.86)
0.60) 0.99 (0.31e3.06)
7.49) 0.52 (0.19e25.0)
d
0.78) d
17.2) 0.0
3.74) 0.83 (0.72e25.5)
10.8) 0.61 (0.12e31.7)
e1.07) d
4.33) 0.45 (0.11e7.70)
3.18) 0.16 (0.005e2.40)
24.1) 0.68 (0.78e48.8)
30.7) 0.48 (0.13e70.7)
ray; TBZ tuberculosis; MDRZmultidrug-resistant; XDRZ Extensively
of Extensively Drug-resistant Tuberculosis Among MDR-TB Isolates
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6 A. Hadizadeh Tasbiti, et alnumber of reported TB cases do not have positive cul-
tures that would enable DSTs to be performed.
The present study indicated three TB cases reported
met the case definition for XDR-TB. One of the three
XDR-TB patients was newly diagnosed and two patients
were treatment failure. No significant difference in
resistance rates was found between new and previously
treated cases (data not shown).
The small number of XDR-TB in Iranian patients
indicates that the problem of resistance to SLD is related
both to the spread of resistant strains and to the devel-
opment of resistance to these drugs during treatment.
Despite insignificant heterogeneity in ORs, all factors
had OR < 1, indicating a decreased risk for M/XDR-TB.
By contrast, some risk factors might have been under-
estimated or failed to be identified. The number of data
available for all factors decreased greatly (> 25% data
unavailable) and thus hampered interpretation of the
comparison.
The numerous risk factors identified for MDR-TB
and the convergence of the epidemics of MDR-TB and
HIV infection call, not only for stronger collaborations
between TB and HIV control, but also for the imple-
mentation of innovative measures to accelerate the
detection of TB resistance and improve treatment
adherence [19]. This study did not identify HIV infec-
tion as a risk factor for drug-resistant TB in Iran. Among
three persons with XDR-TB, one person with HIV
infection died and the other two did not have HIV test
results reported. The acceptance of HIV testing in less
than half of patients, however, was among the limita-
tions of this study, and the association between sex and
HIV positivity should be interpreted with caution.
Many low TB prevalence countries may show fluc-
tuating trends in prevalence of resistance because their
overall burden of TB is low; however, most of these
countries report small absolute numbers of MDR-TB
per year [20]. Based on the WHO classification,
TB incidence or notification rate of  25 per 100,000
per year were defined as high/intermediate and the
remainder was categorized as low TB incidence [21]. In
2012, a total of 10,987 TB cases were reported in Iran,
for a rate of 14.43 cases per 100,000. In comparison
with 2011, the number of TB cases and the case rate
were 11,030 cases and 14.56 cases per 100,000;
respectively. This represents a decrease of 0.9% from
the incidence reported in 2011. Thus, TB case notifi-
cations are stable in Iran, and although TB rates were
increasing in some regions such as Golestan province in
the north of Iran, more recent data show a stabilizing
trend [22].
The prevalence of diabetes mellitus is increasing
rapidly worldwide and has been reported to be signifi-
cantly associated with increased risk of TB [6]. The
association between diabetes and MDR-TB was signif-
icant in this study (OR 1.01, 95% CI 1.09e30.7) which
is similar to other studies. A cohort of clients agedPlease cite this article in press as: Hadizadeh Tasbiti A, et al., Low Level
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10.1016/j.phrp.2016.06.00365 years or more in Hong Kong showed that diabetes
mellitus is associated with TB [23]. Another study in
India indicated that diabetes makes a substantial
contribution to the burden of incident TB in India, and
the association is particularly strong for the infectious
form of TB [24]. This potentially carries a risk with
serious implications for TB control.
In our study, the MDR-TB incidence was negatively
associated with gender (male; OR 0.27, 95% CI
0.18e0.78). The distinction between public health risks
of infection and different lifestyles may account for this
gender difference. Moreover, different contact types with
intensity and duration and differences in experiences of
exposure to M. tuberculosis may result in incidence di-
versity of TB between males and females [6].
Resistance to fluoroquinolones as determined by
OFX was low, 0.7%. This is in contrast to reports from
the United States and eight countries where high rates of
fluoroquinolone-resistant TB were observed [14,17]. In
the present study, the sample size of drug-resistant iso-
lates was small, therefore, only a single fluoroquinolone
was tested. Thus, XDR patients infected with strains
resistant to fluoroquinolones other than this tested could
be misclassified as MDR or drug susceptible TB.
Data included in this study are not the first repre-
sentative information available on M/XDR-TB in Iran;
however, this study had some limitations. The first is the
insufficient quality assurance of drugs susceptibility
testing for SLD and the second is that drugs suscepti-
bility testing is not available for all drugs. Absolute
numbers of M/XDR-TB cases were low in Iran. The
study was designed to estimate the proportion of XDR-
TB and risk factors among MDR patients and was not
powered to detect differences between other patient
subgroups or the administrative divisions in Iran.
However, statistically significant differences could only
be discerned between regions with extreme values. Ef-
forts to diagnose, treat, and prevent spread of M/XDR-
TB need scaling up [25].Conflicts of interest
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